Joep MA Lange

3.4k citations

42 papers · 2.4k indexed · 1 hit paper · h-index 21

Infectious Diseases top 1%
Virology top 0.5%
Epidemiology top 5%
Hepatology top 1%
Immunology top 5%

Co-authors: Birgit HB van Benthem Frank Miedema Marijke Roos Maria Prins Roel A. Coutinho Sigrid A. Otto Mette D. Hazenberg Dörte Hamann
Topics: HIV Research and Treatment (32 papers)HIV/AIDS drug development and treatment (26 papers)HIV/AIDS Research and Interventions (16 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: The Lancet The Journal of Infectious Diseases The Lancet Infectious Diseases
Partner nations: Netherlands Thailand Australia

In The Last Decade

Joep MA Lange

42 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Persistent immune activation in HIV-1 infection is associated with progression to AIDS

2003 577 citations Mette D. Hazenberg, Sigrid A. Otto et al. AIDS profile →

Peers

Countries citing papers authored by Joep MA Lange

Since Specialization

Citations

This map shows the geographic impact of Joep MA Lange's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joep MA Lange with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joep MA Lange more than expected).

Fields of papers citing papers by Joep MA Lange

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joep MA Lange. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joep MA Lange. The network helps show where Joep MA Lange may publish in the future.

Co-authorship network of co-authors of Joep MA Lange

This figure shows the co-authorship network connecting the top 25 collaborators of Joep MA Lange. A scholar is included among the top collaborators of Joep MA Lange based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joep MA Lange. Joep MA Lange is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk of Tuberculosis after Antiretroviral Treatment Initiation: A Comparison between Efavirenz and Nevirapine Using Inverse Probability Weighting 2013 ·Antiviral Therapy ·Sabine Hermans,Yukari C. Manabe,Agnes Kiragga,Andy I. M. Hoepelman,Joep MA Lange,Frank van Leth	1
2	Hepatitis B Virus Prevalence and Vaccine Response in HIV-infected Children and Adolescents on Combination Antiretroviral Therapy in Kigali, Rwanda 2012 ·The Pediatric Infectious Disease Journal ·(unknown),Kimberly R. Boer,(unknown),(unknown),(unknown),Peter Reiss,Joep MA Lange,Sibyl P. M. Geelen	23
3	Public???private partnerships and new models of healthcare access 2008 ·Current Opinion in HIV and AIDS ·Joep MA Lange,(unknown),(unknown),Jacques van der Gaag	4
4	Efavirenz: a review 2007 ·Expert Opinion on Pharmacotherapy ·S.M.E. Vrouenraets,Ferdinand W N M Wit,(unknown),Joep MA Lange	113
5	Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients 2007 ·AIDS ·Reshma Autar,Ferdinand W N M Wit,(unknown),(unknown),(unknown),Elly A. Hassink,Andrew Hill,David A. Cooper,Praphan Phanuphak,Joep MA Lange,David M. Burger,Kiat Ruxrungtham	8
6	HAART for the HIV-infected employees of large companies in Africa 2006 ·The Lancet ·(unknown),Tobias F. Rinke de Wit,(unknown),Maarten F. Schim van der Loeff,(unknown),Joep MA Lange	16
7	GB Virus C Coinfection and HIV‐1 Disease Progression: The Amsterdam Cohort Study 2005 ·The Journal of Infectious Diseases ·Akke K. van der Bij,Nico Kloosterboer,Maria Prins,Brigitte Boeser‐Nunnink,Ronald B. Geskus,Joep MA Lange,R A Coutinho,Hanneke Schuitemaker	65
8	Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27− T cells in HIV-1-infected children 2005 ·AIDS ·Vincent Bekker,(unknown),Henriëtte J. Scherpbier,Jan Weel,Suzanne Jurriaans,(unknown),Frank van Leth,Joep MA Lange,Kiki Tesselaar,Debbie van Baarle,Taco W. Kuijpers	13
9	Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study 2005 ·Antiviral Therapy ·(unknown),Bregt S Kappelhoff,Frank van Leth,Thomas R. MacGregor,Joep MA Lange,Jos H. Beijnen,Alwin D. R. Huitema	78
10	Is the male genital tract really a sanctuary site for HIV? Arguments that it is not 2004 ·AIDS ·(unknown),(unknown),Sjoerd Repping,(unknown),Peter Reiss,Joep MA Lange,Jan M. Prins	35
11	Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort 2004 ·AIDS ·W. Phillip Law,Chris Duncombe,Apicha Mahanontharit,Mark Boyd,Kiat Ruxrungtham,Joep MA Lange,Praphan Phanuphak,David A. Cooper,Gregory J. Dore	122
12	TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen 2003 ·AIDS ·(unknown),Gerrit Jan Weverling,Monika Peeters,(unknown),(unknown),Aza Rakhmanova,Sven A. Danner,Suzanne Jurriaans,Jan M. Prins,Joep MA Lange	33
13	Persistent immune activation in HIV-1 infection is associated with progression to AIDSbreakdown → 2003 ·AIDS ·Mette D. Hazenberg,Sigrid A. Otto,Birgit HB van Benthem,Marijke Roos,Roel A. Coutinho,Joep MA Lange,Dörte Hamann,Maria Prins,Frank Miedema	577
14	Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 2003 ·AIDS ·W. Phillip Law,Gregory J. Dore,Chris Duncombe,Apicha Mahanontharit,Mark Boyd,Kiat Ruxrungtham,Joep MA Lange,Praphan Phanuphak,David A. Cooper	87
15	Limited Sampling Strategies for the Estimation of the Systemic Exposure to the HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Nevirapine 2001 ·Therapeutic Drug Monitoring ·Agnes I. Veldkamp,Rolf P. G. van Heeswijk,Jan W. Mulder,Pieter L. Meenhorst,Richard M. W. Hoetelmans,Joep MA Lange,Jos H. Beijnen	23
16	The Steady‐State Pharmacokinetics of Efavirenz and Nevirapine When Used in Combination in Human Immunodeficiency Virus Type 1–Infected Persons 2001 ·The Journal of Infectious Diseases ·Agnes I. Veldkamp,Marianne Harris,Julio Montaner,Graeme Moyle,(unknown),Mike Youle,M Johnson,(unknown),Hilde Carlier,Remko van Leeuwen,Jos H. Beijnen,Joep MA Lange,Peter Reiss,Richard M. W. Hoetelmans	43
17	Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection 2000 ·AIDS ·Marieke den Brinker,Ferdinand W.N.M. Wit,(unknown),Suzanne Jurriaans,(unknown),Remko van Leeuwen,Nadine G. Pakker,Peter Reiß,(unknown),(unknown),Joep MA Lange	308
18	Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection 1998 ·Journal of Chromatography B Biomedical Sciences and Applications ·Rolf P. G. van Heeswijk,(unknown),(unknown),P. L. Meenhorst,Jan‐Willem Mulder,Joep MA Lange,Jos H. Beijnen	100
19	Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine 1998 ·The Lancet ·Norbert A. Foudraine,Richard M. W. Hoetelmans,Joep MA Lange,Frank de Wolf,Birgit HB van Benthem,Jaap Maas,Ireneus P.M. Keet,Peter Portegies	133
20	Clinical treatment 1992 ·AIDS ·Joep MA Lange,Michael L. Tapper	5

About Joep MA Lange

Joep MA Lange is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 42 papers that have together received 2.4k indexed citations. Recurring topics across this work include HIV Research and Treatment (32 papers), HIV/AIDS drug development and treatment (26 papers) and HIV/AIDS Research and Interventions (16 papers). The work is most often cited by research in Virology (1.4k citations), Infectious Diseases (1.5k citations) and Hepatology (562 citations). Joep MA Lange has collaborated with scholars based in Netherlands, Thailand and Australia. Frequent co-authors include Birgit HB van Benthem, Frank Miedema, Marijke Roos, Maria Prins, Roel A. Coutinho, Sigrid A. Otto, Mette D. Hazenberg, Dörte Hamann, Suzanne Jurriaans and David A. Cooper. Their work appears in journals such as The Lancet, The Journal of Infectious Diseases and The Lancet Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact